Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis

References

• MomtazPPostowMAImmunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathwayPharmgenomics Pers Med2014735736525484597
   PubMedGoogle Scholar
• RosenbergSAYangJCRestifoNPCancer immunotherapy: moving beyond current vaccinesNat Med200410990991515340416
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with pembrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOElHalawaniHFouadMRisk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysisFuture Oncol201511172471248426274495
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOElHalawaniHFouadMRisk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysisExpert Opin Drug Saf201514101507151826394770
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOElHalawaniHFouadMRisk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysisFuture Oncol201612341342526775673
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOElHalawaniHFouadMRisk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysisImmunotherapy20157111213122726513491
   PubMed Web of Science ®Google Scholar
• WestinJRChuFZhangMSafety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialLancet Oncol2014151697724332512
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• GettingerSHornLGandhiLOverall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancerJ Clin Oncol201533182004201225897158
   PubMed Web of Science ®Google Scholar
• NishinoMGiobbie-HurderAHatabuHRamaiyaNHHodiFSIncidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysisJAMA Oncol20162121607161627540850
   PubMed Web of Science ®Google Scholar
• KhungerMRakshitSPasupuletiVIncidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trialsChest Epub201759
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementAnn Intern Med2009151426426919622511
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• FerrisRLBlumenscheinGFayetteJNivolumab for recurrent squamous-cell carcinoma of the head and neckN Engl J Med2016375191856186727718784
   PubMed Web of Science ®Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
   PubMed Web of Science ®Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
   PubMed Web of Science ®Google Scholar
• BellmuntJde WitRVaughnDKeynote-045: open-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancerN Engl J Med20173761015102628212060
   PubMed Web of Science ®Google Scholar
• AntoniaSJLópez-MartinJABendellJNivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (Check-Mate 032): a multicentre, open-label, phase 1/2 trialLancet Oncol201617788389527269741
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• PostowMACallahanMKWolchokJDImmune checkpoint blockade in cancer therapyJ Clin Oncol201533171974198225605845
   PubMed Web of Science ®Google Scholar
• GangadharTCVonderheideRHMitigating the toxic effects of anticancer immunotherapyNat Rev Clin Oncol2014112919924445516
   PubMed Web of Science ®Google Scholar
• CousinSItalianoAMolecular pathways: immune checkpoint antibodies and their toxicitiesClin Cancer Res201622184550455527435397
   PubMed Web of Science ®Google Scholar
• NishinoMShollLMHodiFSHatabuHRamaiyaNHAnti-PD-1-related pneumonitis during cancer immunotherapyN Engl J Med2015373328829026176400
   PubMed Web of Science ®Google Scholar
• EigentlerTKHasselJCBerkingCDiagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyCancer Treat Rev20164571826922661
   PubMed Web of Science ®Google Scholar
• LaiYCLinPCLaiJISuccessful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature reviewInt J Clin Pharmacol Ther201149746146621726497
   PubMed Web of Science ®Google Scholar
• NaidooJWangXWooKMPneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapyJ Clin Oncol201735770971727646942
   PubMed Web of Science ®Google Scholar